XML 21 R9.htm IDEA: XBRL DOCUMENT

INVENTORY

6 Months Ended

Sep. 30, 2025

Inventory Disclosure [Abstract]

Inventory Disclosure [Text Block]

NOTE 3 – INVENTORY

		(in thousands)
		As of September 30, 2025 ($)				As of March 31, 2025 ($)
Raw materials			446				1,104
Finished goods			212				256
Total			658				1,360

During the six months ended September 30, 2025, and 2024, the Company wrote off approximately $1 thousand and $2 thousand in inventory due to abnormal loss due to product expiration, idle facility expense, freight, handling costs, scrap, and wasted material (spoilage). This charge was recorded in Selling, General, and Administrative Expenses. In addition, the Company adjusted approximately $700 thousand of inventory associated with its Vancouver, Washington manufacturing operations as part of the Favorable Contract, described in Note 7 – “Disposition of Assets”.

We capitalize inventory costs related to our investigational drug, provided that management determines there is a potential alternative use for the inventory in future research and development projects or other purposes. As of September 30, 2025, and March 31, 2025, our consolidated balance sheet reported approximately $392 thousand clinical trial-related inventory, respectively.